Progesterone-binding cyst protein in human breast tumor cytosol
- PMID: 3677070
Progesterone-binding cyst protein in human breast tumor cytosol
Abstract
Breast tumor cytosol has been analyzed for the presence of a progesterone-binding protein (PBCP), commonly present in benign breast cysts in huge concentrations. In 377 primary carcinoma investigated PBCP was present in measurable quantities in 60.7% using "rocket" immunoelectrophoresis. Concentrations of PBCP ranged from 0 to 12.4% of total cytosol protein with an average of 4.0 micrograms/mg cytosol protein. The distribution of PBCP values seems to suggest two tumor populations, one of which is lacking in PBCP and the other showing a lognormal distribution. In malignant tumors PBCP levels were negatively correlated (P = 0.024) to estrogen receptor but not to (P = 0.38) progestin receptor levels. There was a highly significant (P less than 0.001) positive correlation to cytosol albumin concentration which suggests an extracellular localization of PBCP possibly caused by restricted lymphatic drainage of tumor tissue. In benign breast tumors, mainly fibroadenomas, both PBCP incidence (81%) and average concentration (13.5 micrograms/mg protein) was higher than in malignant tumors. A positive correlation to sex-hormone receptor levels were observed indicating that PBCP production could be under hormonal control in this type of tumor development. In 71 metastatic tumors examined PBCP incidence was far less than in primary tumors (P less than 0.001) and the levels seen were also considerably lower. PBCP holds promise as a marker of tumors in an early stage of development and/or with a low metastatic potential.
Similar articles
-
Progesterone-binding cyst protein (PBCP = GCDFP-24) and steroid hormone receptors as markers of differentiation in breast cancer. Inverse relation of distribution in normal and malignant tissue of the same breast.Anticancer Res. 1991 May-Jun;11(3):1323-6. Anticancer Res. 1991. PMID: 1888167
-
Progesterone-binding cyst protein (PBCP) in operable breast cancer: correlations with prognostic factors and predictive value for effect of adjuvant tamoxifen treatment.Anticancer Res. 1991 Mar-Apr;11(2):601-5. Anticancer Res. 1991. PMID: 2064314
-
Progesterone binding cyst protein in hormone receptor positive breast cancer; a predictive factor for effect of adjuvant tamoxifen treatment.Anticancer Res. 1994 Sep-Oct;14(5B):2105-8. Anticancer Res. 1994. PMID: 7840507 Clinical Trial.
-
Tumor markers for breast carcinoma.Clin Lab Med. 1982 Sep;2(3):543-65. Clin Lab Med. 1982. PMID: 6754225 Review. No abstract available.
-
[Breast carcinoma metastatic to meningioma: review of the literature and description of 2 new cases].Pathologica. 1995 Oct;87(5):506-12. Pathologica. 1995. PMID: 8868176 Review. Italian.
Cited by
-
Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity.J Clin Med. 2022 Feb 28;11(5):1345. doi: 10.3390/jcm11051345. J Clin Med. 2022. PMID: 35268435 Free PMC article.
-
Expression and prognostic significance of apolipoprotein D in breast cancer.Am J Pathol. 1994 Feb;144(2):310-20. Am J Pathol. 1994. PMID: 8311115 Free PMC article.
-
Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer.Clin Transl Oncol. 2020 Nov;22(11):1952-1962. doi: 10.1007/s12094-020-02354-2. Epub 2020 Apr 18. Clin Transl Oncol. 2020. PMID: 32306242 Free PMC article. Review.
-
Prostate specific antigen--a new constituent of breast cyst fluid.Breast Cancer Res Treat. 1996;38(3):259-64. doi: 10.1007/BF01806144. Breast Cancer Res Treat. 1996. PMID: 8739078
-
The effects and possible mechanism of action of apolipoprotein M on the growth of breast cancer cells.Mol Biol Rep. 2022 Feb;49(2):1171-1179. doi: 10.1007/s11033-021-06945-2. Epub 2021 Nov 13. Mol Biol Rep. 2022. PMID: 34775573
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous